Fungal prosthetic joint infection (PJI) is rare, with Candida species being the most frequently reported pathogen in the medical literature. The risk of relapse following delayed reimplantation arthroplasty for candidal PJI is unknown. We describe 4 new cases and summarize 6 previously reported cases of candidal PJI treated with delayed reimplantation arthroplasty. Ninety percent of the patients received antifungal therapy. Eight patients received amphotericin B either alone or in combination with other antifungals. One patient received fluconazole alone. The median duration of time from resection arthroplasty to reimplantation for total hip and total knee arthroplasties was 8.6 and 2.3 months, respectively. Eight patients did not have relapse of candidal PJI following delayed reimplantation arthroplasty after a median duration of follow-up of 50.7 months (range, 2-73 months). Candidal PJI can be successfully treated with delayed reimplantation arthroplasty after receipt appropriate antifungal therapy.
due to Candida species is unknown, but it is estimated to be ∼1% [18] .
Risk factors for the development of invasive candidal infections include immunosuppression, neutropenia, chronic or prolonged use of antibiotics, presence of indwelling intravenous catheters, parenteral hyperalimentation, malnutrition, diabetes mellitus, rheumatoid arthritis, cirrhosis, history of multiple abdominal surgeries, history of renal transplantation, severe burns, and injection drug use [2, 3, 12, 13, 18, 21] . Despite knowledge regarding these risk factors, approximately one-half of the reported cases of candidal PJI have no identifiable risk factor [3] .
Successful treatment of candidal PJI has been reported, and most often, it has required removal of the joint prosthesis combined with directed antimicrobial therapy. Many investigators have been reluctant to perform delayed reimplantation arthroplasty because of a perceived high risk of relapse of infection. Definitive information regarding therapy is limited; however, recently published practice guidelines for the treatment of candidal infections advise use of resection arthroplasty with antifungal therapy as the standard thera- peutic option and suggest that, after successful therapy, a new prosthesis may be implanted [26] . To date, only 6 such cases have been reported in the literature [12, 15, 17, 23, 25] . We report 4 additional cases and summarize 6 previously reported cases of candidal PJI treated with delayed reimplantation arthroplasty.
PATIENTS AND METHODS

Study design.
To review our experience with candidal PJI and combine this experience with reported cases in the literature, we conducted a retrospective case series and medical literature review. Population. The study population included all patients with a total hip arthroplasty (THA) or total knee arthroplasty (TKA) infections due to Candida species (according to a strict case definition) who were treated with delayed reimplantation arthroplasty during the period of 1969-1999. Cases at the Mayo Clinic were identified retrospectively by use of data from the Mayo Clinic total joint registry [27] , master diagnostic index [28] , and microbiology laboratory. Cases reported in the medical literature from 1966 through 1999 were identified by use of MEDLINE with the search terms "joint prosthesis," "candida," and "infection," and from a secondary search of references obtained from the articles found in the primary MED-LINE search.
Case definitions. We defined candidal PJI as "definite" if у2 cultures of either a joint aspiration specimen or a surgical specimen yielded Candida species, in conjunction with an appropriate clinical syndrome. "Treatment failure" was defined as relapse of candidal PJI or culture-negative PJI (signs and symptoms consistent with PJI) while the patient was receiving continuous antifungal therapy for a previously diagnosed candidal PJI.
RESULTS
Study population.
We identified a total of 46 cases of candidal PJI that occurred during the period of 1969-1999. Of these cases, 30 had been reported elsewhere in the medical literature and 16 were diagnosed at our institution but not previously reported. THA, TKA, and total shoulder arthroplasty PJI accounted for 21 (45.6%), 23 (50.0%), and 2 (4.3%) of the 46 cases, respectively. For the whole series of THA and TKA infections, definitive treatment included 25 permanent resection arthroplasties (56.8%), 10 delayed reimplantation arthroplasties (22.7%), 5 debridements with prosthesis retention (11.4%), 2 direct exchanges (4.5%), 1 amputation (2.3%), and 1 case treated with medical therapy alone (2.3%). Table 1 summarizes the demographic characteristics of the 4 patients at the Mayo Clinic (C1-C4) and the 6 patients described elsewhere who received delayed reimplantation arthroplasties. There were 6 THA and 4 TKA infections in 5 men and 5 women. The initial arthroplasty was cemented in 7 cases and uncemented in 1; in 2 cases, information was not available. Vancomycin-impregnated bone cement was used in 2 of these patients. The median duration of time from prosthesis implantation to the onset of symptoms was 20.3 months (range, 3.0-179.6). The median duration of symptoms (from symptom onset to diagnosis) for the 4 patients treated at our institution was 4.7 months (range, 4.3-5.1 months).
Clinical characteristics and risk factors for invasive candidal disease and PJI are summarized in table 2, and treatment characteristics are summarized in table 3. Six (60%) of 10 patients had identifiable risk factors for Candida infection and/or candidal PJI, with the majority of those patients (5 [83.3%] of 6) having 11 risk factor. These risk factors included previous revision arthroplasties in 6 patients (60%), prior prosthetic joint infections in 4 (40%), antibiotic use within the 3 months before presentation in 3 (30%), rheumatoid arthritis in 2 (20%), use of steroids of immunosuppressive agents in 2 (20%), HIV infection in 1 (10%), and Candida species isolated from a site other than blood (severe candida cystitis with fungal balls) in 1 (10%). Symptoms at presentation included pain in 7 patients (70%), swelling in 3 (30%), warmth in 2 (20%), redness in 1 (10%), sinus tract formation in 1 (10%), and a groin mass in 1 (10%). Insufficient data regarding the median duration of symptoms and risk factors were available to comment on all aspects of the cases reported elsewhere.
Microbiology. No patient had a polymicrobial infection at the time of diagnosis. In all cases, the intraoperative cultures yielded Candida species. Six cases (60%) were due to Candida albicans, 3 (30%) were due to Candida parapsilosis, and 1 (10%) was due to Candida tropicalis. In vitro antifungal susceptibility studies were reported for 50% of the cases (2 Mayo Clinic cases and 3 other reported cases), were not reported for 30%, and were not performed for 20%. Susceptibility testing for the 2 reported Mayo Clinic cases was done by broth microdilution, in accordance with the M27-T reference method of the National Committee for Clinical Laboratory Standards [29] . No information regarding the method of susceptibility testing was available for 3 cases reported in the literature. In all cases in which the results of susceptibility tests were available, the organism was reported to be susceptible to the antifungal agent administered to treat the infection. Prior to diagnosis, 9 patients had provided a preoperative aspirate specimen. Aspirate specimens were positive on Gram stain for yeast or fungal elements for only 2 patients (22.2%); however, culture of these specimens was positive for Candida species for 8 patients (88.9%).
Surgical therapy. Resection arthroplasty was the initial intervention for 8 (80%) of 10 patients. Of the 2 patients for whom resection arthroplasty was not the initial treatment, one [17] had relapse after receiving medical therapy alone, and initial debridement was unsuccessful for the other [25] . Gross purulence was noted in 6 patients (75%) at the time of surgery. Of the 4 patients treated at our institution, staged irrigation and debridement with removal of all cement and necrotic tissue was performed concurrently with resection arthroplasty. Three patients underwent irrigation with saline and 1 underwent irrigation with a saline-neomycin solution. No patient underwent irrigation with a solution that contained amphotericin B or fluconazole. In 1 patient, a polymethylmethacrylate spacer was placed that contained 200 mg of fluconazole. No other patient received local antifungal therapy in the form of antifungal irrigation or impregnated beads or spacers.
The median duration of time from resection arthroplasty to reimplantation for THAs and TKAs was 8.6 months (range, 2.4-17.7 months) and 2.3 months (range, 0.3-6.0 months), respectively. Reimplanted prostheses were cemented in all patients for whom this information was available (6 [60%] of 10). Three of the 6 patients received antibiotic-impregnated bone cement (vancomycin for 1 patient and a combination of vancomycin and tobramycin for 2). No patient received antifungal-impregnated cement at the time of reimplantation. In the 8 cases for which the results of cultures had been reported at the time of reimplantation, the results of fungal cultures were negative. After surgery, 1 patient developed serous drainage. An aspiration specimen obtained 1 week earlier yielded negative results on culture, and at the time of reimplantation, the bone and soft tissues did not appear to be infected; however, 3 intraoperative cultures revealed Staphylococcus epidermidis. The patient was treated with cefazolin for 24 days, followed by treatment with orally administered cephradine.
Medical therapy. Information about medical therapy is summarized in table 4. Systemic antifungal therapy was administered to all but 1 patient; 8 patients (80%) received amphotericin B, of whom 3 (37.5%) received amphotericin B alone, 2 (25%) received concurrent 5-fluorocytosine, and 3 (37.5%) received induction amphotericin B, followed by either (1) fluconazole or (2) ketoconazole followed by fluconazole. The mean total dose of amphotericin B was 1145 mg (range, 500-2100 mg) and the median duration of therapy was 42 days (range, 36-71 days). The median daily dose of fluconazole was 200 mg (range, 25-400 mg) and the median duration of therapy was 122 days (range, 47-269 days); this includes data for 1 patient who received maintenance therapy for suppression. One patient received monotherapy with fluconazole (200 mg per day for 6 weeks) in combination with a fluconazole-impregnated polymethylmethacrylate spacer.
Five adverse events related to antifungal therapy occurred in 4 patients (40%). Three episodes (60%) involved renal insufficiency secondary to use of amphotericin B; 2 of these episodes required a reduction in the dosing frequency and 1 necessitated discontinuation of therapy. Significant gastrointestinal intolerance (i.e., nausea and vomiting) accounted for the remaining 2 adverse events (one patient was receiving 5-fluorocytosine and the other was receiving ketoconazole). Both adverse events required discontinuation of the medication.
Treatment outcome. The median duration of follow-up of the 4 patients at our institution was 60.4 months, and, for all cases, the median duration of follow-up was 50.7 months (range, 2.0-73.1 months) after reimplantation. Eight patients (80%) had no recurrence of candidal PJI after successful delayed reimplantation arthroplasty. However, 2 patients (20%) developed recurrent candidal infection after delayed reimplantation arthroplasty. The first relapse occurred in an HIV-positive individual who had developed a TKA PJI due to C. parapsilosis after 2 arthroplasty revisions for a PJI due to Staphylococcus hominis while receiving suppressive therapy with ciprofloxacin and rifampin [15] . The prosthesis was removed and the patient was treated with amphotericin B followed by ketoconazole. Four months later, he underwent reimplantation. One month after undergoing reimplantation arthroplasty, he relapsed while receiving suppressive ketoconazole. In vitro susceptibility to ketoconazole was confirmed. Because of continued joint instability discovered at the time of relapse, he subsequently underwent above-the-knee amputation.
The second patient developed a TKA PJI due to C. tropicalis 3 months after undergoing prosthesis implantation [25] . She relapsed first after a limited excision and debridement. She relapsed again after undergoing resection arthroplasty and reimplantation at 18 days in conjunction with amphotericin B. This resulted in another resection arthroplasty and arthrodesis, and there was no subsequent evidence of infection. There were no adverse outcomes or subsequent joint revisions documented for the 4 patients treated at our institution (table 3) .
DISCUSSION
The overall incidence of total hip and knee arthroplasty infection ranges from 0.5% to as high as 15% in recent literature [3, [30] [31] [32] [33] [34] . In our experience, the combined incidence rate of combined hip and knee arthroplasty infection during the first 2 years after initial implantation is 5.9 and decreases to 2.3 during the next 10 years [35] . The incidence of fungal PJI is unknown, but it is estimated to constitute ∼1% of all PJIs [18] . Most patients with candidal PJIs present with an indolent onset of symptoms. In the present study, the median duration of symptoms was 20.3 months, which is slightly longer than that reported by Brooks and Pupparo [3] in a recent review (median, 14 months). Sixty percent of the patients in the present study had identifiable risk factors for Candida infection, which is similar to data for cases and reviews in the literature.
Delayed reimplantation arthroplasty offers the best opportunity for a good functional outcome. However, only 10 (21.7%) of a total of 46 patients identified in the literature underwent delayed reimplantation arthroplasty for candidal PJI. Because delayed reimplantation arthroplasty offers the best opportunity for a good functional outcome, we focused on the results of this procedure for treatment of candidal PJI. Most patients with candidal PJI underwent permanent prosthesis removal and subsequently had poor functional outcome. This differs from the common practice of administration of 4-6 weeks of directed antimicrobial therapy followed by delayed reimplantation arthroplasty for total hip and knee PJIs due to other organisms [7, [30] [31] [32] . The overall success rate of delayed reimplantation arthroplasty for total hip and knee arthroplasties varies for all microorganisms (respective ranges, 79%-92% and 63%-89%) [35] . Recurrent infection after delayed reimplantation is a serious complication and often results in permanent removal of the joint prosthesis [32, 36, 37] . On the basis of the current study, a 20% recurrence rate after 2-stage reimplantation for candidal PJI should be anticipated.
Antifungal therapy appears to be an important component in the successful treatment of candidal PJI. Recent guidelines recommend antifungal therapy for candidal PJI similar to that recommended in the guidelines for treatment of native joint arthritis and osteomyelitis; the duration of therapy can range from weeks to months, depending on the selected antifungal agent [26] . Theoretically, early infections treated with thorough irrigation and debridement, with removal of all infected foreign materials, may result in cure for patients who have an intact immune system. In 1988, Lambertus et al. [20] described a patient cured with resection alone; however, the duration of follow-up is unknown. One patient in the current series was treated with surgical therapy alone. He developed a pain and swelling suggestive of a TKA infection 16.5 months after a revision. He underwent debridement of the knee, and all components and cement were removed. Surgical pathologic examination demonstrated acute purulent inflammation, and C. albicans was the only organism yielded by cultures of 2 separate specimens. He underwent reimplantation after 8 days without antifungal therapy and did well for 51 months, when he died of other causes.
The choice of antifungal agents has varied considerably in the cases reported in the literature. Amphotericin B has been used most commonly and has been the cornerstone of therapy for deep-seated candidal infections. Guidelines for treatment of candidal native joint arthritis and osteomyelitis suggest use of amphotericin B and/or fluconazole, because treatment with these agents has been shown to be effective in cases reported elsewhere [26] . Successful treatment of candidal PJI with fluconazole as the sole antifungal agent was reported in 3 cases [4, 9, 11] , and we report an additional case in our series, for a total of 4 cases. Both clinical and experimental data demonstrate high in vivo activity of fluconazole to most Candida species, with good synovial fluid penetration [9, 15, 26] . In a report by Cushing et al. [4] of a patient who received 400 mg of fluconazole per day for treatment of PJI due to C. parapsilosis, serum levels approximated synovial fluid levels and resulted in sterilization of the synovial fluid. In comparison, synovial fluid levels of amphotericin B vary from 20% to 1100% of serum fluid levels, which are sufficient to inhibit growth [38] . Fluconazole also has the additional advantage of being less nephrotoxic than amphotericin B. Although data are limited, therapy with fluconazole appears to be as effective as amphotericin B therapy for susceptible strains when combined with adequate surgical drainage. No studies have been done to document the equivalence of the lipid formulations of amphotericin B to conventional amphotericin B for the treatment of candidal osteomyelitis and PJI. The efficacy of the newer antifungal agents voriconazole and caspofungin is also unknown in this setting. These agents may be an attractive alternative, given their spectrum of activity, reduced toxicity, and ease of administration, but they need to be investigated further.
The total duration of antifungal therapy necessary for eradication of infection is also unknown. In the present study, the duration of treatment ranged from 6 weeks to 9 months, with the median being 6 weeks for patients who received amphotericin B and slightly more than 17 weeks for patients who received fluconazole. Wide variability exists in cases reported elsewhere. The mean total dose of amphotericin B, when used alone or in combination with 5-fluorocytosine, was 1552 mg. For patients who are infected with susceptible organisms and who have an intact immune system, treatment for a minimum of 6 weeks has been most consistently successful in eradicating infection; eradication should be confirmed by culture prior to reimplantation.
The optimal time to reimplantation for patients with candidal PJI has not been determined, because candidal PJIs are notoriously indolent and there is no consistent test for successful eradication. Most studies that have looked at the time to reimplantation have indicated that a TKA may be reimplanted sooner than a THA after a bacterial infection. Although there is considerable variation in the literature regarding the optimal time to reimplantation, successful reimplantation is based on the ability to adequately eradicate the infection [30, 31, 34, 37, 38] . At our institution, reimplantation of THAs typically occurs at 3-6 months after resection arthroplasty is performed, whereas reimplantation of TKA occurs within 6 weeks for S. aureus PJI [39] . In the current study, the average time to reimplantation for THA was longer than that for TKA (8.6 versus 2.3 months, respectively) but was consistent with the time to reimplantation for PJIs due to other organisms at our institution during the same time period [39] . Other investigators have recommended that, for cases of PJI due to unusual or virulent organisms, there should be a longer period of time between resection and reimplantation, because there is no single reliable method to document eradication of infection [31, 34] . Although this provides an opportunity to assess for possible treatment failure after completion of antimicrobial therapy, it also increases patient morbidity.
Current guidelines from the Infectious Diseases Society of America for the treatment of candidal PJI [26] suggest that reimplantation may be done after successful eradication of the infection, as defined by the lack of recurrent symptoms while the patient is not receiving therapy. The infection-free interval period suggested in one study, which was determined on the basis of 2 cases of successful hip reimplantation after candidal PJI, was 3 months [17] . We would agree that a shorter time from resection arthroplasty to reimplantation is possible and may be similar to the current timelines used at our institution for S. aureus PJIs.
Currently, antibiotic-impregnated cement is used in various ways; it is used most commonly in polymethylmethacrylate (PMMA) spacers prior to reimplantation or mixed with cement for fixation during 2-stage reimplantation procedures. The findings of studies regarding its efficacy as primary prophylaxis for bacterial infection have varied and seem to indicate a slight reduction in the overall rate of late infections [40] . One of the potential drawbacks to the use of antibiotic-impregnated bone cement, however, is the increase risk of development of drugresistant organisms [34] . However, there is a greater benefit when antibiotic-impregnated bone cement is used in patients undergoing reconstruction after an infection [7, 35, 40, 41] . In our study, antifungal-impregnated bone cement was used at the time of reimplantation in none of the patients. Although it is not known whether this may be an effective method to reduce the rate of secondary deep fungal infections after reimplantation arthroplasty, fluconazole-impregnated cement possesses antiCandida activity and is an effective adjunctive therapy in a rat model of C. albicans foreign-body osteomyelitis [42] . Further research in this area is necessary.
On the basis of the lessons learned from treating THA and TKA infections due to bacteria, as well as the information gained from our series, a few points can be made. First, delayed reimplantation arthroplasty can be successfully performed after eradication of candidal PJI. Second, a combined medical and surgical approach that includes antifungal therapy (either fluconazole and/or amphotericin B) and confirmation of an infection-free period of time after the initial surgical approach appears to provide the best chance of a successful reimplantation. The optimal duration of antifungal therapy and time to reimplantation remain unknown but may be similar to those for PJIs due to other microorganisms. Local antifungal therapy (antifungal-impregnated beads/spacers) may be an effective adjunct to therapy but needs to be studied further.
